Shanxi C&Y Pharmaceutical Group Co Ltd (300254) — Net Asset Quality Index
Shanxi C&Y Pharmaceutical Group Co Ltd (300254) has a Net Asset Quality Index of 32.4% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥1.59 Billion minus total liabilities of CN¥1.07 Billion yields net assets of CN¥514.07 Million. A higher index indicates a stronger, lower-leverage balance sheet. See Shanxi C&Y Pharmaceutical Group Co Ltd (300254) defensive interval to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Shanxi C&Y Pharmaceutical Group Co Ltd Net Asset Quality Index Over Time (2008–2025)
This chart shows how Shanxi C&Y Pharmaceutical Group Co Ltd's Net Asset Quality Index has evolved across 18 annual periods from 2008 to 2025. As of March 2026, the index stands at 32.4%, representing net assets of CN¥514.07 Million against total assets of CN¥1.59 Billion CNY. Explore cash flow conversion of Shanxi C&Y Pharmaceutical Group Co Ltd to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Shanxi C&Y Pharmaceutical Group Co Ltd (2008–2025)
The table below presents the year-by-year Net Asset Quality Index for Shanxi C&Y Pharmaceutical Group Co Ltd from 2008 to 2025, covering 18 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see Shanxi C&Y Pharmaceutical Group Co Ltd stock valuation.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 36.2% | CN¥594.33 Million | CN¥1.64 Billion | CN¥1.05 Billion | ▼ -2.5 pp |
| 2024 | 38.6% | CN¥598.18 Million | CN¥1.55 Billion | CN¥949.55 Million | ▼ -15.7 pp |
| 2023 | 54.3% | CN¥778.43 Million | CN¥1.43 Billion | CN¥654.64 Million | ▲ +8.3 pp |
| 2022 | 46.1% | CN¥729.68 Million | CN¥1.58 Billion | CN¥854.64 Million | ▼ -2.7 pp |
| 2021 | 48.8% | CN¥744.58 Million | CN¥1.53 Billion | CN¥782.23 Million | ▲ +0.3 pp |
| 2020 | 48.5% | CN¥872.61 Million | CN¥1.80 Billion | CN¥927.91 Million | ▼ -3.3 pp |
| 2019 | 51.8% | CN¥932.60 Million | CN¥1.80 Billion | CN¥869.43 Million | ▼ -10.5 pp |
| 2018 | 62.3% | CN¥931.24 Million | CN¥1.50 Billion | CN¥564.47 Million | ▼ -1.7 pp |
| 2017 | 64.0% | CN¥971.17 Million | CN¥1.52 Billion | CN¥547.42 Million | ▼ -2.7 pp |
| 2016 | 66.7% | CN¥954.85 Million | CN¥1.43 Billion | CN¥477.74 Million | ▼ 0.0 pp |
| 2015 | 66.7% | CN¥872.50 Million | CN¥1.31 Billion | CN¥435.93 Million | ▼ -3.0 pp |
| 2014 | 69.7% | CN¥823.16 Million | CN¥1.18 Billion | CN¥358.17 Million | ▼ -0.7 pp |
| 2013 | 70.4% | CN¥767.16 Million | CN¥1.09 Billion | CN¥323.21 Million | ▼ -8.4 pp |
| 2012 | 78.7% | CN¥651.17 Million | CN¥827.16 Million | CN¥175.99 Million | ▼ -4.0 pp |
| 2011 | 82.7% | CN¥581.17 Million | CN¥702.56 Million | CN¥121.39 Million | ▲ +29.5 pp |
| 2010 | 53.3% | CN¥149.59 Million | CN¥280.84 Million | CN¥131.25 Million | ▲ +7.9 pp |
| 2009 | 45.3% | CN¥117.60 Million | CN¥259.51 Million | CN¥141.91 Million | ▼ -2.3 pp |
| 2008 | 47.6% | CN¥106.70 Million | CN¥224.15 Million | CN¥117.45 Million | — |